Personalis, Inc.

Personalis, Inc. is a genomics company specializing in advanced genomics for precision oncology. Founded in 2011 and incorporated in Delaware, the company's core business revolves around next-generation sequencing (NGS) technologies and molecular profiling platforms. Its mission is to transform the active management of cancer through breakthrough personalized testing, aiming to guide patient care from biopsy throughout their treatment journey. The company's headquarters are located in Fremont, California.

Personalis offers a suite of key products and services designed to provide comprehensive molecular data. These include NeXT Personal, a tumor-informed liquid biopsy test for detecting minimal residual disease (MRD), monitoring therapy response, and tracking recurrence in solid tumor cancers. The ImmunoID NeXT platform is a tissue-based service that combines whole exome and whole transcriptome sequencing with advanced analytics to offer a multi-dimensional view of tumors. Additionally, NeXT Dx provides tumor profiling for therapy selection and clinical trial matching, while the Real-Time Variant Tracker extends NeXT Personal's capabilities to monitor therapy resistance mutations. The company's services, including sequencing and data analysis, cater to pharmaceutical companies, diagnostic firms, research institutions, and cancer patients.

In terms of leadership and recent developments, Chris Hall serves as the Chief Executive Officer, appointed in March 2023. Richard Chen was promoted to President in March 2026, while continuing his role as Chief Medical Officer. Personalis has recently secured significant milestones, including Medicare coverage for its NeXT Personal test for lung cancer surveillance in February 2026 and for breast cancer recurrence surveillance in late 2025. The company reported a substantial increase in clinical test volume in 2025 and projects continued growth for 2026, driven by these coverage expansions. Personalis operates within the competitive and rapidly expanding liquid biopsy market, positioning itself as a leader in ultrasensitive MRD detection and comprehensive genomic profiling.